Speclipse has secured distribution networks for its aesthetic medical device 'PicoCare' in the Middle East and Southeast Asia.


Speclipse Secures Distribution Networks for 'PicoCare' in the Middle East and Indonesia View original image

According to Speclipse on August 4, the company has signed distribution agreements for PicoCare with Imdad, a leading aesthetic medical device distributor in the Middle East, and Beauty World, an aesthetic distribution specialist in Indonesia. Through these agreements, the company has established a foundation to supply PicoCare to Indonesia as well as ten countries in the Middle East and North Africa, including Saudi Arabia, the United Arab Emirates (UAE), Qatar, Kuwait, Oman, and Egypt.


Imdad is the largest specialist distributor of aesthetic medical devices in the Middle East, acting as a local distribution partner for global brands such as Candela Medical and Cynosure. The company boasts 35 years of experience and an extensive sales network in the region. Speclipse plans to leverage Imdad’s sales network and its capabilities in medical staff training and after-sales support to raise awareness of PicoCare and expand its sales channels in the Middle Eastern market.


In Indonesia, after obtaining local regulatory approval in September, PicoCare will be officially introduced at Beauty World's 25th anniversary event. Approximately 1,000 medical professionals and industry officials are expected to attend the event, which will mark the official start of local sales acceleration.



Jung-Hwan Hong, CEO of Speclipse, stated, "Securing distribution networks in the Middle East and Southeast Asia will help expand our overseas supply base and serve as an opportunity to broaden our global sales channels centered on our own brand. Through collaboration with local partners, we will promote the competitiveness of our products and strengthen our position in the global aesthetic medical device market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing